These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 29721396)

  • 1. M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.
    Knudson KM; Hicks KC; Luo X; Chen JQ; Schlom J; Gameiro SR
    Oncoimmunology; 2018; 7(5):e1426519. PubMed ID: 29721396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
    Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
    Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).
    Jochems C; Tritsch SR; Pellom ST; Su Z; Soon-Shiong P; Wong HC; Gulley JL; Schlom J
    Oncotarget; 2017 Sep; 8(43):75217-75231. PubMed ID: 29088859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β.
    Lan Y; Zhang D; Xu C; Hance KW; Marelli B; Qi J; Yu H; Qin G; Sircar A; Hernández VM; Jenkins MH; Fontana RE; Deshpande A; Locke G; Sabzevari H; Radvanyi L; Lo KM
    Sci Transl Med; 2018 Jan; 10(424):. PubMed ID: 29343622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.
    David JM; Dominguez C; McCampbell KK; Gulley JL; Schlom J; Palena C
    Oncoimmunology; 2017; 6(10):e1349589. PubMed ID: 29123964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
    Strauss J; Heery CR; Schlom J; Madan RA; Cao L; Kang Z; Lamping E; Marté JL; Donahue RN; Grenga I; Cordes L; Christensen O; Mahnke L; Helwig C; Gulley JL
    Clin Cancer Res; 2018 Mar; 24(6):1287-1295. PubMed ID: 29298798
    [No Abstract]   [Full Text] [Related]  

  • 7. TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.
    Ye F; Cai Z; Wang B; Zeng C; Xi Y; Hu S; Qu R; Yuan Z; Yue J; Tian Y; Wang X; Fu X; Li L
    Cancer Res; 2023 Jul; 83(13):2262-2277. PubMed ID: 37145144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models.
    Franks SE; Fabian KP; Santiago-Sánchez G; Wolfson B; Hodge JW
    Oncoimmunology; 2022; 11(1):2124666. PubMed ID: 36211806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1.
    Quach HT; Hou Z; Bellis RY; Saini JK; Amador-Molina A; Adusumilli PS; Xiong Y
    Expert Opin Investig Drugs; 2022 Nov; 31(11):1187-1202. PubMed ID: 36448335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa.
    Ozawa Y; Hicks KC; Minnar CM; Knudson KM; Schlom J; Gameiro SR
    Oncoimmunology; 2021 May; 10(1):1915561. PubMed ID: 33996267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
    Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
    Holmgaard RB; Schaer DA; Li Y; Castaneda SP; Murphy MY; Xu X; Inigo I; Dobkin J; Manro JR; Iversen PW; Surguladze D; Hall GE; Novosiadly RD; Benhadji KA; Plowman GD; Kalos M; Driscoll KE
    J Immunother Cancer; 2018 Jun; 6(1):47. PubMed ID: 29866156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel TGFβ Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the Antitumor Immune Response of Anti-PD-L1 Immunotherapy.
    Ludwig N; Wieteska Ł; Hinck CS; Yerneni SS; Azambuja JH; Bauer RJ; Reichert TE; Hinck AP; Whiteside TL
    Mol Cancer Ther; 2021 Jun; 20(6):1102-1111. PubMed ID: 33850003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual targeting of TGF-β and PD-L1 inhibits tumor growth in TGF-β/PD-L1-driven colorectal carcinoma.
    Khalili-Tanha G; Fiuji H; Gharib M; Moghbeli M; Khalili-Tanha N; Rahmani F; Shakour N; Maftooh M; Hassanian SM; Asgharzadeh F; Shahidsales S; Anvari K; Mozafari MR; Ferns GA; Batra J; Giovannetti E; Khazaei M; Avan A
    Life Sci; 2023 Sep; 328():121865. PubMed ID: 37336360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma.
    Strait AA; Woolaver RA; Hall SC; Young CD; Karam SD; Jimeno A; Lan Y; Raben D; Wang JH; Wang XJ
    Commun Biol; 2021 Aug; 4(1):1005. PubMed ID: 34433873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site.
    Wang X; Li X; Ito A; Sogo Y; Ohno T
    Acta Biomater; 2022 Jun; 145():235-245. PubMed ID: 35398544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect.
    Wen X; Zeng X; Cheng X; Zeng X; Liu J; Zhang Y; Li Y; Chen H; Huang J; Guo Z; Chen X; Zhang X
    Mol Pharm; 2022 Oct; 19(10):3612-3622. PubMed ID: 35652897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model.
    Lim S; Park JH; Chang H
    Investig Clin Urol; 2023 Jan; 64(1):74-81. PubMed ID: 36629068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
    Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
    Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.